Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Rilutek
RILUTEK 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085901 · Präparat HOS-083218
In vitro studies using human liver microsomal preparations suggest that CYP 1A2 is the principal
isozyme involved in the initial oxidative metabolism of riluzole. Inhibitors of CYP 1A2 (e.g. caffeine,
diclofenac, diazepam, nicergoline, clomipramine, imipramine, fluvoxamine, phenacetin, theophylline,
amitriptyline and quinolones) could potentially decrease the rate of riluzole elimination, while
inducers of CYP 1A2 (e.g. cigarette smoke, charcoal-broiled food, rifampicin and omeprazole) could
increase the rate of riluzole elimination.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diclofenac (HOS-085903) amitriptyline (HOS-085911) imipramine (HOS-085907) nicergoline (HOS-085905) caffeine (HOS-085902) theophylline (HOS-085910) diazepam (HOS-085904) clomipramine (HOS-085906) phenacetin (HOS-085909) fluvoxamine (HOS-085908) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:14:00Z · SHA-256 28308676bb4846e6870c25018d4060663e4807dea55f5bd8c86ddbf568ed66d2 · Passage 46579b19e7adf1bcce4445191bd46b5d02b5de4a0e063e9ceff4cb863bea1be8 · Zeichen 109–648 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 16
HOS-086244 · Präparat HOS-083284
Antidepressants
Amitriptyline, fluoxetine, imipramine, Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result
nortriptyline, paroxetine, sertraline is expected to increase concentrations of imipramine, amitriptyline, nortriptyline,
fluoxetine, paroxetine or sertraline. Careful monitoring of therapeutic and adverse
effects is recommended when these medicines are concomitantly administered with
antiretroviral doses of ritonavir (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) nortriptyline (HOS-086245) amitriptyline (HOS-085911) imipramine (HOS-085907) sertraline (HOS-086247) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ca4793f824999dcfa7219e45ea966a3c2ccce5545e5e9bc8a5f822aca0176344 · Zeichen 25738–26346 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-086437 · Präparat HOS-083284
Antidepressants
Amitriptyline, fluoxetine, imipramine, Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is
nortriptyline, paroxetine, sertraline expected to increase concentrations of imipramine, amitriptyline, nortriptyline, fluoxetine,
paroxetine or sertraline. Careful monitoring of therapeutic and adverse effects is
recommended when these medicines are concomitantly administered with antiretroviral
doses of ritonavir (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) nortriptyline (HOS-086245) amitriptyline (HOS-085911) imipramine (HOS-085907) sertraline (HOS-086247) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage b8462f15d42c724b252b8e6709037e928a59efa62eec2a00d9c0188b83e98110 · Zeichen 26725–27333 im Abschnitt
Wechselwirkungen · Comtess
Comtess 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-087878 · Präparat HOS-083575
In single-dose studies in healthy volunteers, no interactions were observed between entacapone and
imipramine or between entacapone and moclobemide. Similarly, no interactions between entacapone
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) moclobemide (HOS-087879)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-18T01:00:00Z · SHA-256 fa3d8879d7f9d8835c303451aba5afa0417c9a42bba423f3f71a40c3f8d94d33 · Passage b166fdaf44feb603bbad8e729f534ca1aa5417e38200b4a914c6c7dd6ca62919 · Zeichen 171–365 im Abschnitt
Wechselwirkungen · Comtan
Comtan 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-087903 · Präparat HOS-083583
4
imipramine or between entacapone and moclobemide. Similarly, no interactions between entacapone
and selegiline were observed in repeated-dose studies in parkinsonian patients. However, the
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine,
maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-
structured compounds: rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine,
alpha-methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when
these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) dopamine (HOS-085948) imipramine (HOS-085907) moclobemide (HOS-087879) venlafaxine (HOS-086573) rimiterol (HOS-087904) dobutamine (HOS-086565) apomorphine (HOS-086566) selegiline (HOS-086575) methyldopa (HOS-086564)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T16:36:00Z · SHA-256 5a934525674e083ec4dd9056db2e81d6f6bd7e081e45463e4be2195fdd4c2470 · Passage 607c7c228205279947c9a575e4730f7853ea1c18929afcfc4a48e376ed14e9a1 · Zeichen 322–1089 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-109365 · Präparat HOS-093187
Plasma exposure of omeprazole (CYP 2C19 substrate) 40 mg once daily was increased by 46%
following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to
valdecoxib was unaffected. These results indicate that although valdecoxib is not metabolised by
CYP2C19, it may be an inhibitor of this isoenzyme. Therefore, caution should be observed when
administering Dynastat with medicinal products known to be substrates of CYP2C19 (e.g. phenytoin,
diazepam, or imipramine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) diazepam (HOS-085904) valdecoxib (HOS-109357) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 1174ed6865ef4da5a1bc4cf18b53d520c40718ae93707fd5f081a1005f418d36 · Zeichen 4177–4678 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 23
HOS-109409 · Präparat HOS-093187
Plasma exposure of omeprazole (CYP 2C19 substrate) 40 mg once daily was increased by 46%
following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to
valdecoxib was unaffected. These results indicate that although valdecoxib is not metabolised by
CYP2C19, it may be an inhibitor of this isoenzyme. Therefore, caution should be observed when
administering Dynastat with medicinal products known to be substrates of CYP2C19 (e.g. phenytoin,
diazepam, or imipramine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) diazepam (HOS-085904) valdecoxib (HOS-109357) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 1174ed6865ef4da5a1bc4cf18b53d520c40718ae93707fd5f081a1005f418d36 · Zeichen 4178–4679 im Abschnitt
Wechselwirkungen · Stalevo
Stalevo 50 mg/12.5 mg/200 mg film-coated tablets Stalevo 75 mg/18.75 mg/200 mg film-coated tablets Stalevo 100 mg/25 mg/200 mg film-coated tablets Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Stalevo 200 mg/50 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-112313 · Präparat HOS-093651
Antidepressants: Rarely, reactions including hypertension and dyskinesia have been reported with the
concomitant use of tricyclic antidepressants and levodopa/carbidopa. Interactions between entacapone
and imipramine and between entacapone and moclobemide have been investigated in single dose
studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number
of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and
entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants,
noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal
products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine). No
pharmacodynamic interactions have been observed. However, caution should be exercised when these
medicinal products are used concomitantly with Stalevo (see sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maprotiline (HOS-086572) paroxetine (HOS-086246) desipramine (HOS-086249) imipramine (HOS-085907) moclobemide (HOS-087879) venlafaxine (HOS-086573)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-06T10:34:00Z · SHA-256 efa438d75f473f63d3f59b043f928d6ef3dd686a6813356b7fc3207963682e9f · Passage 8aaf8eda160f67f7912e0de14bb48e24fb25b023852e8cfb4dece046a9b95365 · Zeichen 1018–1973 im Abschnitt
Wechselwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-112874 · Präparat HOS-093777
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine
(40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does
not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if YENTREVE is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage f5263b2aae78af8828902f00ed3e0c2dc4fa81db18866a0b8f1f78e73aa8af66 · Zeichen 2181–2995 im Abschnitt
Wechselwirkungen · Emselex
Emselex 7.5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-113073 · Präparat HOS-093835
Effects of darifenacin on other medicinal products
CYP2D6 substrates
Darifenacin is a moderate inhibitor of the enzyme CYP2D6. Caution should be exercised when
darifenacin is used concomitantly with medicinal products that are predominantly metabolised by
CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine, or tricyclic
antidepressants such as imipramine. The effects of darifenacin on the metabolism of CYP2D6
substrates are mainly clinically relevant for CYP2D6 substrates which are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flecainide (HOS-086203) imipramine (HOS-085907) thioridazine (HOS-086281)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-15T12:10:00Z · SHA-256 de750767f67ad57bdc05ce4c855b9a1fcf428d24652a741d2de5aacfc4e7ad1c · Passage 51bd776005786170df52a4057e481010570058884c6858cd42eefbfc6965c54d · Zeichen 2192–2738 im Abschnitt
Wechselwirkungen · Emselex
Emselex 15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-113095 · Präparat HOS-093835
Effects of darifenacin on other medicinal products
CYP2D6 substrates
Darifenacin is a moderate inhibitor of the enzyme CYP2D6. Caution should be exercised when
darifenacin is used concomitantly with medicinal products that are predominantly metabolised by
CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine, or tricyclic
antidepressants such as imipramine. The effects of darifenacin on the metabolism of CYP2D6
substrates are mainly clinically relevant for CYP2D6 substrates which are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flecainide (HOS-086203) imipramine (HOS-085907) thioridazine (HOS-086281)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-15T12:10:00Z · SHA-256 de750767f67ad57bdc05ce4c855b9a1fcf428d24652a741d2de5aacfc4e7ad1c · Passage 51bd776005786170df52a4057e481010570058884c6858cd42eefbfc6965c54d · Zeichen 2192–2738 im Abschnitt
Wechselwirkungen · Cymbalta
Cymbalta 30 mg hard gastro-resistant capsules Cymbalta 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-113277 · Präparat HOS-093901
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine (40
mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not
affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if Cymbalta is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:40:00Z · SHA-256 a3b2a486f9b4069e76d38032cad9e45c893ee290991d9c0e8b3ea325ef1c101c · Passage 184748d3a5fcda9339ead3f2521f29c9a83708c878d80bf6315817d557c04e72 · Zeichen 2367–3181 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-115320 · Präparat HOS-094267
As stiripentol inhibited CYP2D6 in vitro at concentrations that are achieved clinically in plasma,
substances that are metabolized by this isoenzyme like: beta-blockers (propranolol, carvedilol,
timolol), antidepressants (fluoxetine, paroxetine, sertraline, imipramine, clomipramine), antipsychotics
(haloperidol), analgesics (codeine, dextromethorphan, tramadol) may be subject to metabolic
interactions with stiripentol. A dose-adjustment may be necessary for substances metabolised by
CYP2D6 and that are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) codeine (HOS-090544) carvedilol (HOS-115322) imipramine (HOS-085907) clomipramine (HOS-085906) sertraline (HOS-086247) fluoxetine (HOS-085946) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) timolol (HOS-090571) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a21431794e1268b71b022189130a03e98fd764c99d14f6721c85c72fca8b9c3b · Zeichen 2843–3378 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg hard capsules · Abschnitt 4.5 · PDF-Seite 16
HOS-115384 · Präparat HOS-094267
As stiripentol inhibited CYP2D6 in vitro at concentrations that are achieved clinically in plasma,
substances that are metabolized by this isoenzyme like: beta-blockers (propranolol, carvedilol,
timolol), antidepressants (fluoxetine, paroxetine, sertraline, imipramine, clomipramine), antipsychotics
(haloperidol), analgesics (codeine, dextromethorphan, tramadol) may be subject to metabolic
interactions with stiripentol. A dose-adjustment may be necessary for substances metabolised by
CYP2D6 and that are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) codeine (HOS-090544) carvedilol (HOS-115322) imipramine (HOS-085907) clomipramine (HOS-085906) sertraline (HOS-086247) fluoxetine (HOS-085946) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) timolol (HOS-090571) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a21431794e1268b71b022189130a03e98fd764c99d14f6721c85c72fca8b9c3b · Zeichen 2840–3375 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 27
HOS-115418 · Präparat HOS-094267
As stiripentol inhibited CYP2D6 in vitro at concentrations that are achieved clinically in plasma,
substances that are metabolized by this isoenzyme like: beta-blockers (propranolol, carvedilol,
timolol), antidepressants (fluoxetine, paroxetine, sertraline, imipramine, clomipramine), antipsychotics
(haloperidol), analgesics (codeine, dextromethorphan, tramadol) may be subject to metabolic
interactions with stiripentol. A dose-adjustment may be necessary for substances metabolised by
CYP2D6 and that are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) codeine (HOS-090544) carvedilol (HOS-115322) imipramine (HOS-085907) clomipramine (HOS-085906) sertraline (HOS-086247) fluoxetine (HOS-085946) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) timolol (HOS-090571) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a21431794e1268b71b022189130a03e98fd764c99d14f6721c85c72fca8b9c3b · Zeichen 2847–3382 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 38
HOS-115453 · Präparat HOS-094267
As stiripentol inhibited CYP2D6 in vitro at concentrations that are achieved clinically in plasma,
substances that are metabolized by this isoenzyme like: beta-blockers (propranolol, carvedilol,
timolol), antidepressants (fluoxetine, paroxetine, sertraline, imipramine, clomipramine), antipsychotics
(haloperidol), analgesics (codeine, dextromethorphan, tramadol) may be subject to metabolic
interactions with stiripentol. A dose-adjustment may be necessary for substances metabolised by
CYP2D6 and that are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) codeine (HOS-090544) carvedilol (HOS-115322) imipramine (HOS-085907) clomipramine (HOS-085906) sertraline (HOS-086247) fluoxetine (HOS-085946) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) timolol (HOS-090571) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage a21431794e1268b71b022189130a03e98fd764c99d14f6721c85c72fca8b9c3b · Zeichen 2848–3383 im Abschnitt
Wechselwirkungen · Circadin
Circadin 2 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-115821 · Präparat HOS-094361
Alcohol should not be taken with Circadin, because it reduces the effectiveness of
Circadin on sleep.
Circadin may enhance the sedative properties of benzodiazepines and
non-benzodiazepine hypnotics, such as zaleplon, zolpidem and zopiclone. In a clinical
trial, there was clear evidence for a transitory pharmacodynamic interaction between
Circadin and zolpidem one hour following co-dosing. Concomitant administration
resulted in increased impairment of attention, memory and co-ordination compared to
zolpidem alone.
Circadin has been co-administered in studies with thioridazine and imipramine, active
substances which affect the central nervous system. No clinically significant
pharmacokinetic interactions were found in each case. However, Circadin
co-administration resulted in increased feelings of tranquility and difficulty in
performing tasks compared to imipramine alone, and increased feelings of “muzzy-
headedness” compared to thioridazine alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) thioridazine (HOS-086281) zolpidem (HOS-086327) zaleplon (HOS-115822) zopiclone (HOS-115824)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-07T15:22:00Z · SHA-256 3017f870241dac3ebcc1e9e3316286f78f9cbb94c80634571ffcb14a78331107 · Passage 0e406d4ad6632ada4055b0a88989ef86091edd2aa13d8a7c6cc10414f1e5128c · Zeichen 2494–3540 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-116373 · Präparat HOS-094447
In contrast to these data with
PREZISTA/ritonavir,
PREZISTA/cobicistat may increase these
antidepressant plasma concentrations
(CYP2D6 and/or CYP3A inhibition).
Amitriptyline Clinical monitoring is
Desipramine Concomitant use of boosted PREZISTA recommended when
Imipramine and these antidepressants may increase co-administering boosted
Nortriptyline concentrations of the antidepressant. PREZISTA with these
Trazodone (CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
may be needed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) cobicistat (HOS-088111) trazodone (HOS-086251) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 4f4525e55eb9ba191fea6abaa7ec0b7cfb9e176370ce240a8d85cec068cb4990 · Zeichen 39141–40004 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-116522 · Präparat HOS-094447
Concomitant use of PREZISTA Clinical monitoring is
co-administered with low dose ritonavir recommended when
and these antidepressants may increase co-administering PREZISTA with
concentrations of the antidepressant. low dose ritonavir with these
(CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
Amitriptyline may be needed.
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with PREZISTA
(induction of CYP450 enzymes) co-administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the
use of voriconazole.
Fluconazole Not studied. PREZISTA may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 22f4e74ad4f26762902abfc0033ac15b80ded8bd1a23d2f6a966a8c972097288 · Zeichen 30842–32867 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 99
HOS-116612 · Präparat HOS-094447
In contrast to these data with
PREZISTA/ritonavir,
PREZISTA/cobicistat may increase these
antidepressant plasma concentrations
(CYP2D6 and/or CYP3A inhibition).
Amitriptyline Clinical monitoring is
Desipramine Concomitant use of boosted PREZISTA recommended when
Imipramine and these antidepressants may increase co-administering boosted
Nortriptyline concentrations of the antidepressant. PREZISTA with these
Trazodone (CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
may be needed.
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and
considerations PREZISTA dose adjustment of metformin is
co-administered with cobicistat is recommended in patients who are
expected to increase metformin plasma taking PREZISTA co-administered
concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for PREZISTA
co-administered with ritonavir)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) cobicistat (HOS-088111) trazodone (HOS-086251) ritonavir (HOS-084521) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 2c0dc2d9e3ddb0e0e92026d074dbaae3a3a70393cfdb47a97a09e403e78ecd72 · Zeichen 38675–40185 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.